Holen Sie sich die Stockscreener-App
10.67
0.56%
-0.06
Handel nachbörslich:
10.78
0.11
+1.03%
Schlusskurs vom Vortag:
$10.73
Offen:
$10.99
24-Stunden-Volumen:
2.88M
Relative Volume:
0.43
Marktkapitalisierung:
$1.49B
Einnahmen:
$67.67M
Nettoeinkommen (Verlust:
$-412.69M
KGV:
-2.7884
EPS:
-3.8266
Netto-Cashflow:
$-395.87M
1W Leistung:
-2.29%
1M Leistung:
-36.03%
6M Leistung:
-28.05%
1J Leistung:
-21.52%
1-Tages-Spanne:
$10.63
$11.31
1-Wochen-Bereich:
$10.63
$11.56
52-Wochen-Spanne:
$7.95
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Firmenname
Intellia Therapeutics Inc
Sektor
Branche
Telefon
857-285-6200
Adresse
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
10.67 | 1.50B | 67.67M | -412.69M | -395.87M | -3.8266 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-11-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-11-11 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-11-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-10-28 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-02-28 | Herabstufung | Goldman | Neutral → Sell |
| 2025-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-04-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-03-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Sell |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-06-16 | Eingeleitet | BofA Securities | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-02-18 | Eingeleitet | William Blair | Outperform |
| 2022-02-07 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Eingeleitet | Cowen | Outperform |
| 2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-05 | Eingeleitet | Guggenheim | Buy |
| 2021-09-24 | Eingeleitet | Stifel | Buy |
| 2021-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-07 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Eingeleitet | Truist | Buy |
| 2020-10-14 | Eingeleitet | Wells Fargo | Overweight |
| 2020-09-18 | Eingeleitet | Goldman | Buy |
| 2020-02-28 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-11-01 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-10 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-11-02 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-10-29 | Eingeleitet | Credit Suisse | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Mkt Perform |
| 2018-05-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2017-11-01 | Bestätigt | Jefferies | Buy |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-05 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
NTLA|Intellia Therapeutics Inc|Price:10.730|Chg%:-0.370 - TradingKey
Intellia Therapeutics CFO sells $91,248 in stock By Investing.com - Investing.com UK
NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits
Form 4 Intellia Therapeutics Inc For: 24 July By Investing.com - Investing.com Nigeria
Intellia Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Dulac Edward J III - Moomoo
Intellia Therapeutics CFO sells $91,248 in stock - Investing.com
Intellia Therapeutics (NTLA) CFO logs 8,111-share sell-to-cover tax trade - Stock Titan
Why is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interest - Kavout | AI
Intellia Therapeutics Inc (NTLA) Valuation: PE, PB & Fair Value Analysis - TradingKey
More NTLA, Less RKLB: Cathie Wood’s Latest ARK Trades Explained - Stocktwits
Intellia Therapeutics Stock Short Interest Falls to 44.41% - Quiver Quantitative
Intellia Stock And 2 Growth Shares With Clear Earnings Upside - simplywall.st
(NTLA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Intellia Therapeutics (NTLA) Income Statement & Earnings - Moomoo
NTLA Stock Rockets After Hours Before Critical Data For Genetic Disorder Therapy - Stocktwits
Intellia Therapeutics (NTLA) Dips 4% as Gene Editing Stock Faces Support Test Near $10.81Put Dominated - dars.gov.et
Intellia Therapeutics (NTLA) Resumes Key Trials, Is The Undervalued Case Still Convincing? - Sahm
NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (BLCO) and Intellia Therapeutics (NTLA) - The Globe and Mail
NTLA Downgraded by Wolfe Research -- Rating Changed to Underperf - GuruFocus
Intellia Therapeutics stock trades below recent highs as gene-editing pipeline progresses after late - ad-hoc-news.de
NTLA Downgraded by Wolfe Research -- Rating Changed to Underperform - GuruFocus
This Etsy Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga
Intellia stock downgraded by Wolfe Research on valuation concerns - Investing.com
Intellia Therapeutics: An Overvalued Biotech With Little To No Commercial Potential (NTLA) - Seeking Alpha
4 Best CRISPR Companies to Buy in 2026 and How to Invest - The Motley Fool
Intellia Therapeutics (NTLA) Is Down 12.1% After Positive Phase 3 Lonvo-z Data And 2027 Launch PlansWhat's Changed - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Intellia Therapeutics (NTLA) Could Be 37% Below Fair Value On Gene Editing Hopes - Sahm
NTLA Maintained by Wedbush -- Price Target Raised to $17.00 - GuruFocus
Intellia Therapeutics (NTLA) BofA Securities 2025 Healthcare Conference Summary - Quartr
NTLA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Intellia Therapeutics (NTLA) Short Interest & Short Float | Updated Jul 2026 $NTLA - MarketBeat
Intellia Therapeutics Inc. (NTLA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Intellia Therapeutics (NTLA) Could Be 37% Undervalued After Phase 3 Lonvo Z Success - Yahoo Finance
Wedbush Raises Intellia Therapeutics Price Target to $17 From $12, Maintains Neutral Rating - Moomoo
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock? - Yahoo Finance
Intellia Therapeutics (NTLA) Stock Looks Rich On Sales But Weak On Returns - Yahoo Finance
NTLA Stock Price Prediction 2025-2026 | Intellia Therapeutics Inc Forecast - 24/7 Wall St.
Finanzdaten der Intellia Therapeutics Inc-Aktie (NTLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):